Everything you need to know about BPC-157 — mechanisms, dosage, safety, legality, and research applications — organized by category.
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a protective protein found in human gastric juice. It consists of 15 amino acids and has been studied extensively in animal models for its tissue repair, anti-inflammatory, and neuroprotective properties.
Yes. BPC-157 is a pentadecapeptide — a peptide chain of 15 amino acids. Its molecular weight is 1419.53 Da and its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val.
BPC-157 is a synthetic analog of a naturally occurring sequence found in human gastric juice. The full-length protein (BPC) is naturally produced in the stomach, but the 15-amino-acid research compound (BPC-157) is synthesized in a laboratory.
BPC stands for Body Protection Compound. The designation reflects the compound's origin in gastric juice, which naturally protects the stomach lining from damage.
Most published research uses 200–500 mcg/day. The most common protocol is 250 mcg twice daily (500 mcg/day total) administered subcutaneously. Some researchers use lower doses (200–300 mcg/day) for maintenance or GI applications.
BPC-157 can be administered subcutaneously (under the skin), intramuscularly, or orally. Subcutaneous injection is most common in research protocols. Oral administration is used specifically for GI research, as BPC-157 is stable in gastric acid. Intranasal administration is used in some neurological research.
Most research protocols run 4–12 weeks. Acute injury protocols typically use 4–6 weeks. Chronic condition protocols use 8–12 weeks. Some researchers run 12–16 week protocols for complex injuries or GI conditions.
Yes. BPC-157 is unusually stable in gastric acid, making oral administration effective for GI applications. For systemic effects (tendon, muscle, neurological), subcutaneous injection is more reliable as oral bioavailability for systemic absorption is variable.
BPC-157 acts through multiple mechanisms: upregulation of growth hormone receptors in tendon and muscle tissue, promotion of angiogenesis (new blood vessel formation) via VEGF, modulation of nitric oxide signaling, suppression of inflammatory cytokines (IL-1b, TNF-a), and promotion of collagen synthesis. It also crosses the blood-brain barrier and modulates dopaminergic and serotonergic systems.
BPC-157 accelerates tendon healing by promoting angiogenesis in avascular tendon tissue, increasing collagen synthesis, and organizing collagen fiber deposition. Animal studies show 40–60% faster tendon healing vs controls, with superior biomechanical properties and reduced scar tissue formation.
BPC-157 was originally isolated from gastric juice and has the strongest published evidence base for GI applications. It promotes mucosal healing, reduces intestinal permeability, improves SIBO markers, and protects against NSAID-induced GI damage. GI applications typically show the fastest onset of effects (3–7 days).
BPC-157 does not directly stimulate muscle protein synthesis like growth hormone or IGF-1. Its muscle benefits are primarily through accelerated repair of muscle tears and reduced inflammation. It upregulates growth hormone receptors in muscle tissue, which may enhance the anabolic response to training, but it is not a direct anabolic agent.
Animal studies show BPC-157 has a favorable safety profile with no observed adverse effects at research doses. No toxicity has been reported in published animal studies. Human clinical trial data is limited, so the full safety profile in humans has not been established. It is sold for research purposes only.
Published animal research reports minimal side effects. Some research subjects report mild injection site reactions (redness, swelling) with subcutaneous administration. No serious adverse events have been reported in published research. The absence of human clinical trials means the full side effect profile is unknown.
BPC-157 upregulates growth hormone receptors in tissue but does not directly increase circulating growth hormone, IGF-1, testosterone, or other hormones. It does not suppress the hypothalamic-pituitary axis. Post-cycle therapy (PCT) is not required after BPC-157 research protocols.
No published research shows BPC-157 promotes tumor growth or carcinogenesis. Some animal studies have examined its effects in cancer models, with mixed results. There is no evidence of carcinogenic activity at research doses. However, human long-term safety data is not available.
BPC-157 is legal to purchase for research purposes in the United States. It is not FDA-approved for human use and cannot be sold for human consumption. It is classified as a research chemical. Legal status varies by jurisdiction — see our full legal status guide for country-specific information.
Research-grade BPC-157 is available from specialized peptide suppliers. When evaluating suppliers, look for third-party COAs, HPLC purity testing ≥98%, and mass spectrometry sequence verification. Purgo Labs provides all three with downloadable COAs for every batch.
Research-grade BPC-157 typically costs $30–$80 per 5 mg vial. Lower prices often indicate lower purity or lack of third-party testing. Quality suppliers with full COA documentation typically charge $40–$70 per 5 mg vial.
Authentic research-grade BPC-157 should come with a third-party COA showing HPLC purity ≥98% and mass spectrometry confirmation of the correct molecular weight (1419.53 Da). Any supplier unable to provide these documents should be avoided.
BPC-157 is studied for tendon and ligament repair, muscle healing, GI mucosal repair, SIBO treatment, bone fracture healing, joint and cartilage repair, neurological applications (anxiety, depression, neuroprotection), and systemic anti-inflammatory effects.
Yes. Common research combinations include BPC-157 + TB-500 for enhanced musculoskeletal repair, BPC-157 + Ipamorelin/CJC-1295 for combined repair and growth hormone stimulation, and BPC-157 + Selank for neurological research. Always research compound interactions before combining.
BPC-157 and TB-500 have complementary mechanisms. BPC-157 primarily promotes angiogenesis and collagen synthesis. TB-500 promotes actin polymerization and cell migration. BPC-157 has more published joint and GI-specific data. TB-500 has broader systemic effects. Many researchers use both compounds together for musculoskeletal repair.
Purgo Labs provides pharmaceutical-grade BPC-157 with third-party COAs. Use code HEALTH for 15% off.
Buy BPC-157 at Purgo LabsMedical Disclaimer: All content on this site is for educational and research purposes only. Research peptides are not FDA-approved for human use. Always consult a qualified healthcare professional before considering any peptide or supplement protocol. Nothing on this site constitutes medical advice, diagnosis, or treatment.